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Abstract
The serine/ threonine kinases, Akt1/PKB, Akt2/PKB,
and Akt3 /PKB, play a critical role in preventing
cancer cells from undergoing apoptosis. However,
the function of individual Akt isoforms in the tumor-
igenicity of cancer cells is still not well defined. In the
current study, we used an Akt1 antisense oligonucleo-
tide (AS) to specifically downregulate Akt1 protein in
both cancer and normal cells. Our data indicate that
Akt1 AS treatment inhibits the ability of MiaPaCa-2,
H460, HCT-15, and HT1080 cells to grow in soft agar.
The treatment also induces apoptosis in these cancer
cells as demonstrated by FACS analysis and a
caspase activity assay. Conversely, Akt1 AS treatment
has little effect on the cell growth and survival of
normal human cells including normal human fibro-
blast (NHF) , fibroblast from muscle (FBM) , and
mammary gland epithelial 184B5 cells. In addition,
Akt1 AS specifically sensitizes cancer cells to typical
chemotherapeutic agents. Thus, Akt1 is indispensable
for maintaining the tumorigenicity of cancer cells.
Inhibition of Akt1 may provide a powerful sensitization
agent for chemotherapy specifically in cancer cells.
Neoplasia (2001) 3, 278–286.
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Introduction
For an animal to maintain tissue homeostasis, it must keep
the balance between cell growth and cell death [1,2] .
Perturbation of the balance, either too much cell growth or
too little cell death, will result in tumorigenesis [1,3] .
Recently, Akt has been implicated to play a critical role in
preventing cancer cells from undergoing apoptosis [4,5] . Akt
is a serine/ threonine protein kinase originally identified as a
cellular homologue of viral oncogene Akt8 [6] . It was also
cloned as a kinase that is homologous to cAMP dependent
kinase (PKA) and protein kinase C (PKC) [7,8] . The three
isoforms of Akt (Akt1/PKB, Akt2 /PKB, and Akt3/PKB )
share high homology with 78% to 84% protein sequence
identity [4,9] . The domain structures of Akts are well
conserved from human to C. elegans [4 ] . They all contain
an N-terminal pleckstrin homology (PH) domain, a kinase
domain and a C- terminal hydrophobic domain [4] .
Akt is activated through the phosphatidylinositol 3-kinase
(PI-3K) pathway upon growth factor stimulation [10,11] .
The products of PI -3K, especially phosphatidylinositol [3–5]
triphosphate (PIP3) and phosphatidylinositol [3,4] bisphos-
phate (PIP2) , can bind to the PH domain of Akt [12,13] . The
binding of PIP3 and PIP2 to PH domain of Akt targets the
protein to membrane [14] , where it can be phosphorylated
and activated by PDK1 and ILK [15–18] . These latter
enzymes phosphorylate Akt at threonine 308 and serine 473,
respectively [17,18] , although the phosphorylation of Ser-
473 has also been suggested through an autophosphoryla-
tion mechanism [19] . Activated Akt phosphorylates specific
targets, including Bad, caspase-9, forkhead transcription
factors, IkB kinase kinase ( IKK) [20–23] , thereby promot-
ing cell survival.
Many lines of evidence indicate that Akts are involved in
tumorigenesis. Akt is constitutively activated in PTEN
negative cancer cells [24,25] . PTEN is a tumor suppressor
gene frequently mutated in many advanced tumors [25,26] .
PTEN downregulates the activity of Akt by acting as a
phosphatase that reverses the effect of PI-3K [24–26] . Akt1
is amplified in gastric adenocarcinomas [27] . Akt2 is
overexpressed in 10% to 20% pancreatic and ovarian
cancers [28] . Akt3 is overexpressed in estrogen receptor-
deficient breast cancers and androgen- independent prostate
cancer cells [29] .
Although Akts play critical roles in preventing cells from
undergoing apoptosis, it is not clear whether all Akts are
required for the tumorigenesis of cancer cells, nor is it clear
how important individual Akts are in the process. In this
report, we used Akt1 antisense oligonucleotide (AS) to study
the function of Akt1 in cancer cell growth and survival. We
found that Akt1 AS reduced Akt1 protein expression, inhibited
the ability of cancer cells to grow in soft agar, induced
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apoptosis, and specifically sensitized cancer cells, but not
normal cells, to typical chemotherapeutic agents.
Materials and Methods
All chemicals were from Sigma (St. Louis, MO).
AlamarBlue was from BioSource International (Camarillo,
CA) . Protein concentration was determined using BCA
method according to the manufacturer’s instructions
(Pierce, Rockford, IL) .
Cell Lines
All tumor cell lines were obtained from American Type
Culture Collection (Rockville, MD). Normal human fibro-
blast (NHF) and fibroblast from muscle (FBM) were
obtained from Clonetics (Walkersville, MD). 184B5 cells
were fromNIH. Cells were cultured in the conditions provided
by the suppliers.
Antisense Oligonucleotide Transfection
The 20 -O -methoxyethyl (20 -MOE) chimeric phosphor-
othioate oligonucleotides for Akt1 antisense- Isis#28949
(AS) and the mismatch control - Isis#104566 (MS) were
provided by Isis Pharmaceuticals. The first four and last four
bases on the oligos are with 20 -MOE modification. The
remaining 10 bases on the oligos are regular deoxynucleo-
tides. Cells were transfected with Akt1 AS or MS oligos using
lipofectin reagent (Gibco BRL, Gaithersburg, MD) at a ratio
of 3 l lipofectin /ml Opti -MEM (Gibco BRL) per 100 nM
oligo. Four hours after transfection, cells were incubated with
normal complete media.
Western Blot Analysis
Rabbit anti -Akt1 antibody was from New England
BioLabs (Beverly, MA) . Sheep anti -Akt2 antibody was from
Upstate Technology (Lake Placid, NY). Anti -cytochrome c
antibody and anti -PARP antibody were from Pharmingen
(San Diego, CA). Immunoblot analysis was performed with
the horseradish peroxidase-conjugated goat anti -sheep
(Akt2) , or goat anti - rabbit IgG (Akt1) , or sheep anti -mouse
IgG (cytochrome c and PARP) by using enhanced
chemiluminescence (ECL) Western blotting detection
reagent (Amersham, Arlington Heights, IL) as described
previously [30] .
AlamarBlue Cell Proliferation Assay
The alamarBlue assay was conducted according to the
manufacturer’s instruction. Briefly, cells in 96-well plates
were washed with 200 l PBS, followed by addition of 200 l
of the complete medium containing 10% alamarBlue to
each well. After 3 hours at 378C in a CO2 incubator, the
plate was read on fmax SoftmaxPro (Molecular Devices,
Sunnyvale, CA) using the following filter pair: Ex544/
Em590.
Flow Cytometry Analysis
Cells were harvested by pooling attached and detached
cells and pelleted by centrifugation at 800g for 5 minutes at
48C. The cells were washed with PBS and resuspended in
0.5 ml ice-cold staining solution (5 g/ml propidium iodide
(PI) , 40 U/ml RNase A, 0.5% Triton X-100, in PBS). After 1
hour at 48C in the dark, the DNA content was analyzed using
a Beckton Dickinson ExCalibur flow cytometer (San Jose,
CA) .
Caspase Activity Assay
Cells with 100 l culture medium in 96-well plate were
lysed in 20 l of lysis buffer ( in mM: 10 Hepes, pH 7.5, 35
KCl, 4 MgCl2, 0.1 EDTA, 0.1 EGTA, 0.2 PMSF, 1.0 DTT,
1protease inhibitor cocktail tablet; Boehringer Mannheim,
Mannheim, Germany) at room temperature for 20 minutes,
followed by addition of 80 l of the caspase reaction buffer
containing 48 mM Hepes, pH 7.5, 292 mM sucrose, 0.1%
CHAPS (Calbiochem, San Diego, CA), 1 mM Ac-DEVD-
AMC (Bachem, King of Prussia, PA) . After mixing, the
plate was read on Cytofluor series 4000 (Applied Bio-
systems) using the following setting: excitation=360/40,
emission=460/40, gain=38, cycle=1. After 3 hours incu-
bation at 378C, the plate was read again. The units of
fluorescence change per hour (dFU/h) are defined as
caspase activity.
Soft Agar Growth Assay
The soft agar growth assay was performed as described
[31] . These assays were carried out in 10% fetal calf serum.
For the bottom layer of agar, 1 ml of 0.5% agar was placed in
each 35-mm-diameter well of six -well plates. Then 2 ml of
0.3% top agar containing 1104 cells was layered on top of
the solidified layer of bottom agar. After 2 weeks, the
colonies were stained with p - iodonitrotetrazolium violet and
the number of colonies were scored by counting the colonies
using the image analysis program Image-Pro Plus (Media
Cybernetics, Silver Spring, MD).
Preparation of cell extracts
Cells from 10-cm Petri dishes were harvested and lysed
in 200 l buffer B ( in mM: 20 Hepes, pH 7.5, 10 NaCl, 20
EDTA, 1 EGTA, 5 sodium pyrophosphate, 2 sodium
orthovanadate, 10  -glycerophosphate, and 1% NP-40)
on ice for 30 minutes. The samples were centrifuged at
12,000g at 48C for 10 minutes. The supernatants were
used as cell extracts.
Preparation of Cytosolic Fractions from MiaPaCa-2 Cells
The isolation of cytosolic fractions from MiaPaCa-2
cells was carried out as described [32] . Briefly, MiaPaCa-
2 cells were harvested and washed with ice-cold PBS and
resuspended in five volumes of buffer A ( in mM: 20
Hepes, pH 7.5, 10 KCl, 1.5 MgCl2, 1 sodium EDTA, 1
sodium EGTA, 1 DTT, and 0.1 PMSF) containing 250 mM
sucrose. The cells were homogenized with 10 strokes of a
Teflon homogenizer. The homogenates were centrifuged
twice at 750g for 10 minutes at 48C. The supernatant
was further centrifuged at 100,000g for 1 hour at 48C,
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and the resulting supernatant was designated as cytosolic
fraction.
Results
Protein Level of Akt1 and Akt2 in Different Cancer Cell Lines
We examined the expression levels of Akt1 and Akt2 in a
panel of cancer cell lines. Western blot analysis shows that
Akt1 and Akt2 proteins are expressed in all the cancer cell
lines tested here (Figure 1 ) .
Akt1 AS Reduced Akt1 Protein Level
We used an antisense oligonucleotide ( Isis#28949)
specific for Akt1 to study the effect of inhibiting Akt1 in
cancer cells (Figure 2A ) . A mismatch oligonucleotide
( Isis#104566) containing six nucleotide substitutions was
used as a control (Figure 2A ) . Twenty- four hours after
transient transfection, Akt1 and Akt2 protein levels in these
transfected cells were measured by Western-blot analysis.
As shown in Figure 2B, 250 nM Akt1 AS oligo reduced Akt1
protein level between 47% and 82% in HeLa, MiaPaCa-2,
H460, and HCT-15 cells. The Akt2 protein levels, however,
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Figure 1. Akt1 and Akt2 protein levels in cancer cell lines. Cells were cultured
and cell extracts were prepared as described in Materials and Methods
section. Fifty micrograms of the cell extracts prepared from different cell lines
were loaded to 10% SDS polyacrylamide gels and subjected to Western blot
analysis using Akt1 and Akt2 antibodies as described in Materials and
Methods section.
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Figure 2. Akt1 AS reduced Akt1 protein level in cancer cells. (A ) The nucleotide sequences of Akt1 antisense (AS) and mismatch control (MS) . (B ) HeLa,
MiaPaCa -2, H460, and HCT-15 cells were transfected with 250 nM Akt1 AS or MS as described in Materials and Methods section. Twenty - four hours after
transfection, cells were harvested and extracts were prepared as described in Materials and Methods. Fifty micrograms of the extracts were subjected to Western
blot analysis using Akt1 or Akt2 antibodies as described in Materials and Methods. The density of the protein bands were measured using a Bio -Rad GS-710
calibrated imaging densitometer.
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were not affected by the Akt1 AS oligo (Figure 2B ) . Similar
effects were observed in other cancer cell lines including
PC3, LnCaP, HT1080, and DLD1 (data not shown).
Akt1 AS Inhibited the Proliferation of Cancer Cells
To test the effect of Akt1 AS on cancer cells, we chose five
cancer cell lines from different tissues and performed the
alamarBlue cell proliferation assay after treating them with
Akt1 AS for various amounts of time (Figure 3 ) . Compared
to lipofectin control, Akt1 AS treatment results in a great
decrease in the number of viable cells with less than 20% in
HT1080, HeLa and MiaPaCa-2 cells forty-eight hour after
transfection (Figure 3A;C ;E ) , respectively. Viable cells
(25% and 37%) were observed for H460 and HCT15 after
72-hour treatment with Akt1 AS (Figure 3B and D ) . The
Akt1 MS also showed some nonspecific toxicity in the assay
(Figure 3 ) .
Akt1 AS Inhibited the Ability of Cancer Cells to Grow in Soft
Agar
One of the hallmarks of cancer cells is their ability to
grow in an anchorage- independent manner. So we tested
whether Akt1 AS treatment on cancer cells would affect
their growth in soft agar. As shown in Figure 4, the number
of colonies formed by HT1080 cells after Akt1 AS
treatment were only about 20% of that of lipofectin control,
whereas the MS oligo–transfected HT1080 cells generated
70% colonies of the lipofectin control (Figure 4 ) . Similar
effects were observed for MiaPaCa-2, H460 and HCT15
cells (Figure 4 ) .
Akt1 AS Induced Cancer Cells to Undergo Apoptosis
Akt1 is critical for the survival of cancer cells. According to
flow cytometry analysis (Figure 5A and C ) , 18.7% of
MiaPaCa-2 cells, 24% of HeLa cells, 21% of HT1080 cells,
4% of H460, and 3.5% of HCT-15 cells undergo apoptosis
24 hours after treatment with Akt1 AS oligo, whereas very
few cells (e.g., 0.3% for MiaPaCa) were dying in MS oligo–
transfected cells. To make sure the cells were dying through
apoptosis, instead of through nonspecific necrosis, we
examined the status of cytochrome c in cytosol and cleavage
of poly-ADP ribose polymerase (PARP), two of the
biochemical hallmarks of apoptosis. A time course treatment
on MiaPaCa-2 cells was carried out using Akt1 AS and MS,
and cell extracts as well as cytosolic fractions were prepared
from the corresponding cells. Western blot analysis showed
that more cytochrome c was present in the cytosol of Akt1
AS–transfected cells (Figure 5B ) , indicating the release of
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Figure 3. Akt1 AS inhibits cancer cell proliferation. At day 0, 3000 cells ( per well ) were plated into 96 -well Costar plates. At day 1, cells were transfected with 250
nM Akt1 AS, or MS, or lipofectin control as described in Materials and Methods section. The alamarBlue assay was performed at various time points as described in
Materials and Methods. Data are representative of two independent experiments with eight replicates for each point. Shown is the mean±SD of the eight replicates.
Neoplasia . Vol. 3, No. 4, 2001
Inhibition of Akt1 Suppresses the Tumorigenicity of Cancer Cells Liu et al. 281
cytochrome c from mitochondria to cytosol. The PARP
cleavage started at 20 hours after Akt1 AS transfection, and
very little PARP precursor was left at 40 hours after Akt1 AS
transfection (Figure 5B ) . The timing of release of cyto-
chrome c correlated well with the timing of PARP cleavage
(Figure 5B ) , suggesting that cell death occurred through
apoptosis instead of nonspecific necrosis.
Akt1 AS Did Not Induce Apoptosis in Normal Cells
We also tested the effect of Akt1 AS treatment on three
normal cell lines by FACS analysis. As shown in Figure 6, 24
hours after Akt1 AS treatment, only 0.9% of NHF cells
undergo apoptosis whereas Akt1 MS treatment has 0.8%
apoptotic cells, although Akt1 AS reduces Akt1 protein in the
cells by 75%. A similar effect was observed in other normal
cells including FBM and mammary gland epithelial 184B5
cells (Figure 6 ) .
Akt1 AS Sensitized Cancer Cells to Chemotherapeutic
Treatment
Because Akt has been shown to protect cancer cells from
a variety of apoptotic stimuli - induced cell death [5,33–35] ,
we hypothesized that Akt1 AS would sensitize cancer cells to
chemotherapeutic agent- induced apoptosis. We therefore
tested the combination effects of Akt1 AS treatment and the
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Figure 5. Akt1 AS induced apoptosis in cancer cells. HeLa, MiaPaCa -2, HT1080, H460 or HCT15 cells were transfected with 250 nM Akt1 AS or MS using lipofectin
as described in Materials and Methods section. After 24 hours, FACS analysis was carried out as described in Materials and Methods. (A ) FACS analysis for
MiaPaCa -2 cells treated with Akt1 AS and MS. (B ) MiaPaCa -2 cells were transfected with Akt1 AS or MS at 250 nM concentration for the indicated times. Cells
were harvested. Half of them was used to prepare cytosolic fractions, and the other half was used to prepare cell extracts as described in Materials and Methods. 30
g of cytosolic fractions or 50 g of cell extracts were subjected to Western blot analysis for cytochrome c and PARP, respectively. (C ) Summary of the apoptotic
population by FACS analysis and Akt1 protein reduction by Western blot in five cancer cell lines after Akt1 AS treatment.
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Figure 4. Akt1 AS oligo inhibited cancer cell growth in soft agar. HT1080 cells,
MiaPaCa -2 cells, NCI -H460 cells or HCT-15 cells were transfected with 250
nM Akt1 AS or MS oligos as described in Materials and Methods section.
Twenty - four hours after transfection, cells were harvested and 10,000 live
cells were plated to a soft agar assay as described in Materials and Methods.
Data were expressed as the percentage of colony number with lipofectin
transfected cells as 100%. Shown is the mean±SD of three experiments.
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chemotherapeutic agent etoposide or doxorubicin on H460
and HCT-15 cells, which are quite resistant to etoposide or
doxorubicin. As shown in Figure 7A, Akt AS treatment alone
in H460 cells induced 41 units of caspase activity and
doxorubicin treatment alone induced 22 units of caspase
activity. However, combination treatment with Akt1 AS and
doxorubicin resulted in 92 units of caspase activity, indicating
a synergistic effect. On the contrary, the Akt1 MS treatment
together with doxorubicin did not result in significant change
in caspase activity. The synergistic effect was also observed
in HCT15 cells after Akt1 AS and doxorubicin treatment
(Figure 7B ) , and in both cell lines with Akt1 AS and
etoposide treatment (Figure 7D and E ) . In addition to these
tumor cell lines, we also tested the effect of Akt1 AS in
combination with doxorubicin or etoposide on the NHF cell
line. As shown in Figure 7C and F , either Akt1 AS, or
doxorubicin, or etoposide alone generated very little caspase
activity, and no synergistic effect was observed.
Discussion
Akt1 Is Critical for Cancer Cell Growth and Survival
Apoptosis is a built - in process that clears away the
damaged, unnecessary, or abnormal cells in metazoan
organisms [2] . Cancer cells are abnormal cells and differ
from normal cells in many aspects [3 ] . To sustain the
tumorigenicity, cancer cells must gain the ability to avoid
apoptosis [3] . Akts are key proteins that prevent cancer
cells from undergoing apoptosis. It seems that three Akts
(Akt1, Akt2, and Akt3) have the same substrate specificity
because they all can phosphorylate Bad in vitro (Liu X,
FBM
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Figure 6. Akt1 AS had little effect on the survival of normal human cells. NHF, FBM or 184B5 cells were transfected with 250 nM Akt1 AS or MS for 24 hours. Cells
were harvested, with one third of the cells subjected to FACS analysis, and the other two - thirds subjected to Western blot analysis for Akt1 as described in Materials
and Methods section.
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unpublished data) . In addition to Akt1, Akt2 has been shown
to phosphorylate Bad in vivo [36] . Thus, it is difficult to
differentiate the function of individual Akt isoform by over-
expressing the protein in cells. To investigate the role of Akt1
in cancer cells, we tested the effect Akt1 antisense in several
different cancer cell lines including a colon cancer cell line
(HCT-15) , a lung carcinoma cell line (H460) , a pancreatic
cancer cell line (MiaPaCa-2) , a cervix adenocarcinoma cell
line (HeLa) , and a fibrosarcoma cell line (HT1080) . Akt1
AS treatment greatly reduced the growth of these tumor cells
in both anchorage-dependent (Figure 3 ) and anchorage-
independent manner (Figure 4 ) . It also induced apoptosis in
all these cancer cells (Figure 5 ) . These cancer cell lines are
from different tissues and carry various gene mutations such
as Ras and p53 mutations [37–39] . The fact that Akt1 AS
targeting Akt1 greatly inhibited the proliferation of these
tumor cells suggests that Akt1 plays an important role in the
malignant phenotype of these cells. Although Akt1 MS oligo
did not cause any reduction of Akt1 protein, it did show some
nonspecific toxicity as indicated in Figures 3–5B. However,
the nonspecific toxicity has very little effect on the apoptosis
of these cancer cells 24 hours after transfection (Figure 5A
and data not shown) .
The high protein sequence homology and similar sub-
strate specificity [9,36] among Akts raises the possibility
that the three Akts may be able to compensate each other.
The above statement is supported by the observation that
Akt1 AS oligo had no effect on the growth or apoptosis of
Panc1 cells where Akt2 is overexpressed (data not shown).
The redundant function of Akts might also explain that Akt1
AS treatment on PC3 cells did not induce apoptosis although
the Akt1 protein level can be reduced by more than 50%
(data not shown). Because there is more Akt3 than Akt1 in
PC3 cells [29] , the reduction of Akt1 by Akt1 AS could be
compensated by Akt3.
Given the fact that constitutively activated Ras resulted in
the activation of PI3-kinase/Akt pathway in the cancer cells
tested here (MiaPaCa-2, HT1080, HCT-15, and H460)
[40] , Akt may play a very important role in the survival of
these cancer cells. Indeed, downregulation of Akt1 induced
them to undergo apoptosis (Figures 5 and 7 ) , even though
we did not detect high levels of constitutively active Akts in
A B                                                       C
D                                                           E F
0
20
40
60
80
10 0
12 0
Lip AS MS
H 4 6 0  c e l l s
dF
U
/h
r
DMSO Dox(1.5μM)
0.0 0
10.0 0
20.0 0
30.0 0
40.0 0
50.00
60. 00
70. 00
80. 00
90. 00
Lip AS MS
H 4 6 0  c e l l s
dF
U
/h
r
DMSO Etoposide (100μM)
0
5
10
15
20
25
30
35
40
Lip AS MS
H C T 1 5  c e l l s
dF
U
/h
r
DMSO Dox (1.5μM)
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
Lip AS MS
H C T 1 5  c e l l s
dF
U/
hr
DMSO Etoposide (100μM)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Lip AS MS
NHF
dF
U/
hr
DMSO Etoposide (100 μM)
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Lip AS MS
N H F
dF
U
/h
r
DMSO Dox (1.5μM)
Figure 7. Akt1 AS sensitized cancer cells to chemotherapeutic drugs. At day 0, 20,000 of H460 or NHF, or 40,000 of HCT15 cells ( per well ) were plated into 96 -well
Costar plates. At day 1, cells were transfected with 250 nM Akt1 AS, or MS, or lipofectin control as described in Materials and Methods section. After 24 hours, 1.5 M
doxorubicin was added to HCT15 cells for 15 hours (B ) , to H460 cells for 8 hours (A ) , and to NHF cells for 24 hours (C ) followed by caspase activity assay as
described in Materials and Methods. In another experiment, 24 hours after transfection, 100 M etoposide was added to H460 (D ) , or HCT -15 (E ) , or NHF cells
(F ) for 24 hours followed by caspase activity assay as described in Materials and Methods. Data are representative of two independent experiments with four
replicates for each point. Shown is the mean±SD of the four replicates.
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these cells (data not shown) . The process is probably due to
the dephosphorylation of pro-apoptotic proteins such as
Bad, caspase-9 or forkhead transcription factors after Akt1
protein reduction. Although we failed to identify the phos-
phorylation status of Bad and AFX in these cells through
Western blot analysis (antibodies from New England
BioLabs) , we were able to detect the upregulation of p27
in H460 and MiaPaCa-2 cells treated with Akt1 AS (Liu X,
unpublished data) , suggesting the dephosphorylation of
AFX [41] in response to Akt1 protein reduction.
Interestingly, Akt1 AS treatment had no discernable effect
on the growth and survival of normal cells such as NHF,
FBM, and 184B5 cells (Figure 6 ) . Although more normal cell
lines need to be tested, these data suggest that a specific
inhibitor for Akt1 may be a useful chemotherapeutic agent.
The tumor cell–specific effects of Akt1 inhibition could be
due to the fact that cancer cells are more vulnerable to Akt1
protein reduction than normal cells because some cancer
cells are more dependent on Akt1.
Akt1 AS Sensitized Cancer Cells to Typical
Chemotherapeutic Agents
Doxorubicin and etoposide are topoisomerase II inhibitors
that have been shown to induce apoptosis in a number of
tumor cell lines [42,43] . These agents have also been used
in combination with other agents in the treatment of certain
tumors [44] . An advantage of combination chemotherapy is
that certain combinations have synergistic effects when
compared with either agent alone [45,46] . Our data show
that downregulation of Akt1 alone is sufficient to sensitize
H460 and HCT15 cells to doxorubicin or etoposide induced
apoptosis (Figure 7 ) . It suggests the possibility for the
combination treatment of cancer using Akt1 specific inhib-
itors and cytotoxic drugs such as etoposide or doxorubicin in
future clinical applications.
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